• Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a highly collegial group that is dedicated to the pursuit of excellence and advancement of critical care research in Canada.
  • Canadian Critical Care Trials Group
    The CCCTG has are more than 30 research programs underway and over 100 peer-reviewed publications to its credit, with direct impact on clinical practice in critical care.
  • Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a national organization of more than 300 individuals with research interests in the management of the critically ill patient.
  • Canadian Critical Care Trials Group
    Endorsement by the CCCTG communicates our full commitment to ensure that the work is undertaken in a rigorous and ethical manner, and communicated in a timely and effective way.
Coordinates

Institution

Sunnybrook Health Sciences Centre

City

Toronto

Contact This Member

Rob Fowler

Rob Fowler is an Associate Professor of Medicine at the University of Toronto, an internist and intensivist, and Director of Research for the Department of Critical Care Medicine and the Department of Medicine at Sunnybrook Health Sciences Centre.

Rob Fowler received his medical degree at McGill University, his residency training at the University of Toronto, and completed a critical care fellowship and Master of Science degree at Stanford University. He is a past Clinician-Scientist of the Ontario Ministry of Health and Long-term Care and a current Clinician-Scientist of the Heart and Stroke Foundation.

Rob’s academic interests include the access and outcomes of care for critically ill patients, with a particular interest on end-of-life care. He was the critical care lead for the American Thoracic Society statement on the Association between Health Insurance Status and Access, Care Delivery, and Outcomes for Patients Who Are Critically Ill; has investigated differential use of critical care resources according to gender and age; and, has highlighted how selective patient inclusion in clinical trials leads to deceased generalizability of all our research findings. During the 2003 SARS epidemic, he helped provide the first descriptions of critically ill patients and modes of disease transmission. More recently, working with colleagues throughout North America, Asia, Europe and Australia, Rob helped international research programs to study clinical characteristics, treatments and outcomes of patients with H1N1-related critical illness. Rob has previously examined costs of caring for the critically ill and is the lead investigator of a multi-country economic evaluation of venous thromboembolism prevention in the ICU.